Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway

Carcinogenesis

Volumn 35, Issue 2, 2014, Pages 452-460

  Shukla, Sanjeev ^a   Bhaskaran, Natarajan ^a   Babcook, Melissa A ^a,b   Fu, Pingfu ^b   MacLennan, Gregory T ^b   Gupta, Sanjay ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; BIM PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P27; SERINE; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VENTRAL LOBE; PROSTATE VOLUME; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TRANSGENIC MOUSE; TUMOR VOLUME; UPREGULATION;

ADENOCARCINOMA; ANIMALS; APIGENIN; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84893387803     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt316     Document Type: Article

References (50)

1. Siegel,R. et al. (2013) Cancer statistics, 2013. Cancer J. Clin., 63, 11-30.
2. Siegel,R. et al. (2012) Cancer treatment and survivorship statistics, 2012. Cancer J. Clin., 62, 220-241.
3. Prostate cancer facts and statistics on the American Cancer Society website. http://www.cancer.org/cancer/prostatecancer/index.
4. Sircar,K. et al. (2009) PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J. Pathol., 218, 505-513.
5. Blando,J. et al. (2009) PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am. J. Pathol., 174, 1869-1879.
6. Nardella,C. et al. (2010) Faithfull modeling of PTEN loss driven diseases in the mouse. Curr. Top. Microbiol. Immunol., 347, 135-168.
7. West,K.A. et al. (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat., 5, 234-248.
8. Katoh,M. et al. (2013) Cancer genetics and genomics of human FOX family genes. Cancer Lett., 328, 198-206.
9. Zhang,Y. et al. (2011) FoxO family members in cancer. Cancer Biol. Ther., 12, 253-259.
10. Zhao,Y. et al. (2011) Applications of post-translational modifications of FoxO family proteins in biological functions. J. Mol. Cell Biol., 3, 276-282.
11. Tzivion,G. et al. (2011) FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim. Biophys. Acta, 1813, 1938-1945.
12. Sunters,A. et al. (2003) FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J. Biol. Chem., 278, 49795-49805.
13. Li,R. et al. (2007) Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum. Pathol., 38, 1501-1507.
14. Shukla,S. et al. (2009) Deregulation of FOXO3A during prostate cancer progression. Int. J. Oncol., 34, 1613-1620.
15. Lynch,R.L. et al. (2005) The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol. Cancer Res., 3, 163-169.
16. Liu,J.W. et al. (2005) Induction of prosurvival molecules by apoptotic stimuli: involvement of FOXO3a and ROS. Oncogene, 24, 2020-2031.
17. Yang,L. et al. (2005) Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J. Biol. Chem., 280, 33558-33565.
18. Chen,Q. et al. (2010) Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One, 5, e15288.
19. Shankar,S. et al. (2008) Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin. Cancer Res., 14, 6855-6866.
20. Li,Y. et al. (2007) Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J. Biol. Chem., 282, 21542-21550.
21. Shukla,S. et al. (2010) Apigenin: a promising molecule for cancer prevention. Pharm. Res., 27, 962-978.
22. Shukla,S. et al. (2007) Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle, 6, 1102-1114.
23. Franzen,C.A. et al. (2009) The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase/Src signaling mechanism. Cancer Prev. Res. (Phila)., 2, 830-841.
24. Wang,G. et al. (2008) Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells. Mol. Cell. Biochem., 316, 91-97.
25. Shukla,S. et al. (2004) Molecular mechanisms for apigenin-induced cellcycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol. Carcinog., 39, 114-126.
26. Shukla,S. et al. (2005) Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate, 64, 224-239.
27. Hollman,P.C. et al. (1999) Dietary flavonoids: intake, health effects and bioavailability. Food Chem. Toxicol., 37, 937-942.
28. Kaplan-Lefko,P.J. et al. (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate, 55, 219-237.
29. Shukla,S. et al. (2007) Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res., 67, 6925-6935.
30. Shukla,S. et al. (2007) Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int. J. Cancer, 121, 1424-1432.
31. Shukla,S. et al. (2013) Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice. Prostate, 73, 1507-1517.
32. Shukla,S. et al. (2012) Apigenin attenuates insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model. Pharm. Res., 29, 1506-1517.
33. Carnero,A. (2010) The PKB/AKT pathway in cancer. Curr. Pharm. Des., 16, 34-44.
34. Majumder,P.K. et al. (2005) Akt-regulated pathways in prostate cancer. Oncogene, 24, 7465-7474.
35. Trotman,L.C. et al. (2006) Identification of a tumour suppressor network opposing nuclear Akt function. Nature, 441, 523-527.
36. Wang,S. et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 4, 209-221.
37. Zhong,B. et al. (2010) Induction of clusterin by AKT-role in cytoprotection against docetaxel in prostate tumor cells. Mol. Cancer Ther., 9, 1831-1841.
38. Wang,H. et al. (2013) Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma. Clin. Cancer Res., 19, 158-169.
39. Kagawa,S. et al. (2012) Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. J. Surg. Res., 178, 758-767.
40. Chandramohan,V. et al. (2004) Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels. J. Immunol., 172, 5522-5527.
41. van Gorp,A.G. et al. (2006) Chronic protein kinase B (PKB/c-akt) activation leads to apoptosis induced by oxidative stress-mediated Foxo3a transcriptional up-regulation. Cancer Res., 66, 10760-10769.
42. Kops,G.J. et al. (2002) Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature, 419, 316-321.
43. Shukla,S. et al. (2008) Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. Free Radic. Biol. Med., 44, 1833-1845.
44. Romagnolo,D.F. et al. (2012) Flavonoids and cancer prevention: a review of the evidence. J. Nutr. Gerontol. Geriatr., 31, 206-238.
45. Hui,C. et al. (2013) Flavonoids, flavonoid subclasses and breast cancer risk: a meta-analysis of epidemiologic studies. PLoS One, 8, e54318.
46. Kyle,J.A. et al. (2010) Dietary flavonoid intake and colorectal cancer: a case-control study. Br. J. Nutr., 103, 429-436.
47. Bosetti,C. et al. (2006) Flavonoids and prostate cancer risk: a study in Italy. Nutr. Cancer, 56, 123-127.
48. Gates,M.A. et al. (2009) Flavonoid intake and ovarian cancer risk in a population-based case-control study. Int. J. Cancer, 124, 1918-1925.
49. Meyer,H. et al. (2006) Bioavailability of apigenin from apiin-rich parsley in humans. Ann. Nutr. Metab., 50, 167-172.
50. Abdulkader,I. et al. (2005) Cell-cycle-associated markers and clinical outcome in human epithelial cancers: a tissue microarray study. Oncol. Rep., 14, 1527-1531.